Healthcare Royalty HCRX 深 沪
等待开盘 11-03 09:30:00 美东时间
0.00
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 总市值 0
- 52周最高 0.00
- 市盈率 静 0.00
- 换手率 0.00%
- 52周最低 0.00
- 委 比 0.00%
- 总股本 2.15亿
- 历史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 0.00
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
Nanobiotix has entered into a $71 million royalty-based financing agreement with HealthCare Royalty to extend its cash runway into early 2028. The funding supports development in head and neck cancer and lung cancer, and enables self-sustainability and growth of next-generation nanotherapeutic platforms. HealthCare Royalty will receive a capped portion of milestones and royalties on JNJ-1900 (NBTXR3). The upfront payment is $50 million, with an a...
10-31 07:00
ADC Therapeutics to Present at November Investor Conferences
LAUSANNE, Switzerland, Oct. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today ann...
10-27 19:15
ADC Therapeutics Announces $60 Million Private Placement
LAUSANNE, Switzerland, Oct. 13, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today ann...
10-13 19:30
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, Oct. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today anno...
10-02 04:05
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, Aug. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today anno...
08-02 04:05
ADC Therapeutics Makes Grant to New Employee Under Inducement Plan
LAUSANNE, Switzerland, July 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today anno...
07-02 04:05
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, June 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today anno...
06-03 04:05
REGENXBIO announces royalty monetization agreement for up to $250M
REGENXBIO (NASDAQ:RGNX) announced on Monday the closure of a non-dilutive, limited recourse royalty bond agreement of up to $250M with Healthcare Royalty (HCRx). This agreement monetizes select antic...
05-20 04:14
REGENXBIO Announces Closure Of Non-Dilutive, Limited Recourse Royalty Bond Agreement Of Up To $250M With Healthcare Royalty
$150 million secured at closing extends cash runway into early 2027REGENXBIO retains additional potential non-dilutive funding opportunities, including monetization of Priority Review Voucher (PRV) and milestones from
05-20 04:08
ADC Therapeutics to Present at Upcoming Investor Conferences
LAUSANNE, Switzerland, May 15, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today anno...
05-15 19:15
